Aiforia signs a deal with an Italian hospital in Catania
The collaboration involves the use of the Aiforia Clinical AI solutions for the analysis of tissue samples from breast and prostate cancer patients, as well as the use of the Aiforia AI model development platform. The total value of the contract is approximately EUR 250 thousand for three years.
The contract is part of an initiative to accelerate the diagnostic workflow and automate the image analysis at the anatomic pathology laboratory of Gravina Hospital. The main provider in this tender is an RTI GPI A.S.P lead consortium, and Aiforia is one of their subcontractors.
“We are excited to announce our second large clinical project in Italy this year. This partnership further enhances our standing in the European clinical pathology market and underscores the acknowledgment that our solutions align with the requirements of clinical pathology laboratories,” says Jukka Tapaninen, CEO of Aiforia.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Securities Ltd
ubs@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com
SOURCE: CISION
